We are developing objective and quantitative assessment tools that measure cerebellar function in combination with a modernised movement assessment test. We believe this has the potential to revolutionise the way we assess and study ADHD and ASD – two diagnoses that affect several hundred thousand children in Sweden alone. In

A large international study on ~8000 individuals from 8 countries followed for up to 20 years revealed biomarker to predict diabetes. Based on the discovery, LDcoder® was develop at Lundoch Diagnostics, which efficiently predicts the risk of diabetes at least four year before the disease actually develops. In this project,

We want to make a significant difference to the lives of people with PD and their families. Our specific aim is to verify and patent a new technology for the treatment of PD. Our technology (adaptive DBS) makes it possible to adapt the treatment to the individual’s changing needs, which

The glymphatic system is fundamental to the understanding of common diseases from multiple sclerosis to dementia. Currently, there is no non-invasive method to track the clearance of brain metabolites by the glymphatic system and thus link preclinical research with clinical research in this area. This work is the first time

The incidence of invasive Group A Streptococcus (GAS) reached the highest ever recorded figures in Sweden last year. In the event of an invasive infection, the bacterium spreads like wildfire in the body. Sepsis is difficult to detect at an early stage and the course of the disease is rapid,

The main objective of this project is to explore the potential of using the outer ear; including the concave side of the pinna, the external and internal auditory canal, and the tympanic membrane, as a platform to gain further understanding of how alternative pathways through the skin contribute to transdermal

Every day I see patients who die prematurely or lose quality of life due to low blood pressure. A PVC that can be placed quickly and safely yet deliver large volumes of fluid rapidly would save lives and preserve quality of life for patients surviving critical illness. Difficulty establishing free

Mutations in the estrogen receptor are responsible of resistance to standard treatments, and so far no effective alternative drug regimens have been implemented in the clinic. We believe that our proteogenomic workflow can be applied to analyze clinical samples with expressed estrogen receptor mutations to derive alternative drug targets and

Our project aims to diagnose and characterise sepsis and ultimately tailor the treatment of sepsis and ARDS using protein profiles. Today, new proteomics methods (such as mass spectrometry) can analyse thousands of proteins at a time from a drop of blood. Our hope is that with protein profiling and artificial

Classical tissue engineering strategies are patient-specific, thus clearly associated with inherent limits: a time-consuming graft production and a complex/costly production. Most importantly those cell-based strategy only allows for autologous use of the generated grafts. Here, we will validate the large-scale production and pre-clinical performance of a unique bone graft substitute.